Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
Top Cited Papers
- 31 May 2011
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 118 (5), 831-839
- https://doi.org/10.1016/j.ophtha.2010.09.004
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBritish Journal of Ophthalmology, 2009
- The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degenerationProgress in Retinal and Eye Research, 2008
- Vascular endothelial growth factor in eye diseaseProgress in Retinal and Eye Research, 2008
- Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivoExperimental Eye Research, 2007
- Targeting VEGF-A to Treat Cancer and Age-Related Macular DegenerationAnnual Review of Medicine, 2007
- Targeting Vascular Endothelial Growth FactorDrugs & Aging, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigenJournal of Molecular Biology, 1999
- The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic PotencyOnline Journal of Public Health Informatics, 1996